Supercharged immune cells take on Hard-to-Treat head and neck cancer
NCT ID NCT07617805
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for adults with advanced head and neck cancer that has spread or come back. The treatment uses donor immune cells that are engineered to target two cancer markers, EGFR and HER2. Participants first receive chemotherapy to prepare their body, then get the engineered cells. The goal is to find a safe dose and see if the cells can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EGFR/HER2 dual-target CAR-NK cells (engineered immune cells from a donor) plus chemotherapy drugs fludarabine and cyclophosphamide
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced head and neck cancer that has not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 42 participants, so results may not apply broadly. The treatment involves chemotherapy and engineered cells, which can cause serious side effects like infections or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOMARKER-POSITIVE EGFR/HER2- EXPRESSING HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug combo targets Hard-to-Treat head and neck cancer
- New chemo combo shows promise for tough head and neck cancers
- Drug combo shows promise for tough head and neck cancers
- New drug combo shows promise for Tough-to-Treat head and neck cancer
- New vaccine combo aims to control advanced head and neck cancer
- Ultrasound boosts cancer drug in tiny trial